DE69531607D1 - Fusionsgene für den inhibitor des terminalen komplements und proteine - Google Patents

Fusionsgene für den inhibitor des terminalen komplements und proteine

Info

Publication number
DE69531607D1
DE69531607D1 DE69531607T DE69531607T DE69531607D1 DE 69531607 D1 DE69531607 D1 DE 69531607D1 DE 69531607 T DE69531607 T DE 69531607T DE 69531607 T DE69531607 T DE 69531607T DE 69531607 D1 DE69531607 D1 DE 69531607D1
Authority
DE
Germany
Prior art keywords
inhibitor
proteins
fusion genes
terminal complement
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69531607T
Other languages
English (en)
Other versions
DE69531607T2 (de
Inventor
P Rother
Scott Rollins
P Squinto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69531607D1 publication Critical patent/DE69531607D1/de
Publication of DE69531607T2 publication Critical patent/DE69531607T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE69531607T 1994-03-03 1995-03-01 Fusionsgene für den inhibitor des terminalen komplements und proteine Expired - Fee Related DE69531607T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20572094A 1994-03-03 1994-03-03
US205720 1994-03-03
PCT/US1995/002944 WO1995023512A1 (en) 1994-03-03 1995-03-01 Terminal complement inhibitor fusion genes and proteins

Publications (2)

Publication Number Publication Date
DE69531607D1 true DE69531607D1 (de) 2003-10-02
DE69531607T2 DE69531607T2 (de) 2004-06-17

Family

ID=22763363

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69531607T Expired - Fee Related DE69531607T2 (de) 1994-03-03 1995-03-01 Fusionsgene für den inhibitor des terminalen komplements und proteine

Country Status (8)

Country Link
US (1) US5847082A (de)
EP (1) EP0750458B1 (de)
JP (1) JPH09510088A (de)
AU (1) AU683158B2 (de)
CA (1) CA2184356A1 (de)
DE (1) DE69531607T2 (de)
ES (1) ES2204944T3 (de)
WO (1) WO1995023512A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843884A (en) * 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
US6319897B1 (en) * 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
GB9614871D0 (en) * 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US6498285B1 (en) 1997-08-06 2002-12-24 Alexion Pharmaceuticals, Inc. Methods for producing transgenic pigs by microinjecting a blastomere
GB9807520D0 (en) 1998-04-09 1998-06-10 Univ Wales Medicine Modified biological material
GB9905503D0 (en) 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
JP3543106B2 (ja) 1999-07-21 2004-07-14 大阪大学長 膜結合型ｃ１インアクチベーター
WO2002002621A2 (en) * 2000-06-30 2002-01-10 Zymogenetics, Inc. Mammalian secreted proteins
GB0016811D0 (en) * 2000-07-07 2000-08-30 Adprotech Ltd Lipid rafts
CN1524002A (zh) * 2001-06-08 2004-08-25 ��˹��ŵ�� 治疗或预防产胰岛素细胞的移植排斥反应
US20030086940A1 (en) * 2001-08-10 2003-05-08 Cristina Costa Engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
SI1549333T1 (sl) 2002-09-20 2012-02-29 Univ Pennsylvania Analogi kompstatina z izboljĺ ano aktivnostjo
ES2346978T3 (es) 2003-11-04 2010-10-22 Novartis Vaccines And Diagnostics, Inc. Uso de anticuerpos monoclonantes anti-cd40 antagonistas para el tratamiento del mieloma multiple.
EP1694360B1 (de) 2003-11-04 2010-08-04 Novartis Vaccines and Diagnostics, Inc. Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat-abstossung
WO2005044304A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
EP2236172A1 (de) 2003-11-04 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Kombinationstherapie mit anti-CD20 und anti-CD40 Antikörper zur Behandlung von B-Zell Krebsarten
EP2301575A1 (de) 2003-11-04 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Verfahren zur Therapie von soliden Tumoren mit CD40-Zelloberflächenantigenexpression
JP4178281B2 (ja) 2004-12-08 2008-11-12 シリオン セラピューティクス， インコーポレイテッド レチノール関連疾患を処置するための方法、アッセイおよび組成物
JP5421590B2 (ja) 2005-05-18 2014-02-19 ノバルティス アーゲー 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
CA3065947C (en) 2005-10-18 2023-03-07 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
PT1960422E (pt) 2005-11-28 2012-08-16 Univ Pennsylvania Análogos de compstatina potentes
EA018301B1 (ru) 2006-04-21 2013-07-30 Новартис Аг Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение
PL2698166T3 (pl) 2006-10-10 2016-03-31 Regenesance B V Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
ES2681478T3 (es) 2008-08-28 2018-09-13 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
US20130058931A1 (en) 2010-03-11 2013-03-07 University Of Louisville Research Foundation, Inc. Methods of predicting and decreasing the risk of pregnancy loss
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
WO2012078968A2 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
JP6249949B2 (ja) 2011-09-07 2017-12-20 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 薬物動態特性の改善されたコンプスタチンアナログ
WO2013126006A1 (en) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
US9132171B2 (en) 2012-05-23 2015-09-15 Wisconsin Alumni Research Foundation Test of insulin as a drug to reduce restenosis of vessels
CA3133302A1 (en) 2012-07-20 2014-01-23 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US10414814B2 (en) * 2014-07-03 2019-09-17 City Of Hope Tumor-selective CTLA-4 antagonists
WO2016115275A1 (en) * 2015-01-13 2016-07-21 City Of Hope Ctla4-binding protein peptide-linker masks
EP4242298A2 (de) 2016-12-02 2023-09-13 Taiga Biotechnologies, Inc. Nanopartikelformulierungen
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5573940A (en) * 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
WO1995004756A1 (en) * 1993-08-11 1995-02-16 Alexion Pharmaceuticals, Inc. Complement inhibitor proteins of non-human primates
US5521066A (en) * 1993-09-13 1996-05-28 Bristol-Myers Squibb Company Periplasmic membrane-bound system for detecting protein-protein interactions
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins

Also Published As

Publication number Publication date
AU683158B2 (en) 1997-10-30
WO1995023512A1 (en) 1995-09-08
EP0750458A1 (de) 1997-01-02
US5847082A (en) 1998-12-08
JPH09510088A (ja) 1997-10-14
ES2204944T3 (es) 2004-05-01
EP0750458B1 (de) 2003-08-27
AU1985895A (en) 1995-09-18
DE69531607T2 (de) 2004-06-17
CA2184356A1 (en) 1995-09-08
EP0750458A4 (de) 1997-06-11

Similar Documents

Publication Publication Date Title
DE69531607D1 (de) Fusionsgene für den inhibitor des terminalen komplements und proteine
DE742842T1 (de) Gasbehandlung von metallschmelze
DE69627188T2 (de) Brille und brillenfassung
ATE351910T1 (de) Ob-fusionsprotein enthaltende zusammensetzungen und verfahren
ATE283851T1 (de) Inhibitoren von mikrosomalem triglycerid-transfer-protein und verfahren
DE69631065D1 (de) Verbessertes mittel zur verringerung des fliesswiederstandes von schlamm
DE69532671D1 (de) Endoprothesen und stents
DE69835148D1 (de) Chirurgische clips und klemmen
DE69607474D1 (de) Anordnung von elektrode und anschlussklemme
DE69835020D1 (de) Plasmabrenner und verwendungsverfahren dieses plasmabrenners
NO990296D0 (no) HPPD-genet og inhibitorer
ATE214693T1 (de) Aminoguanidine und alkoxyguanidine als protease- hemmer
ATE280213T1 (de) Waschemittelzusammensetzungen mit proteasen und verbesserten amylasen
DE69616028D1 (de) Isolator und hochfrequenzsteckverbinder
DE69826811D1 (de) Zusammensetzungen für die Verwendung bei der Behandlung und Prävention von Hyperurikämie
DE69526002T2 (de) Aufladegerät und Aufladevorrichtung
DE69513831T2 (de) Semicarbazid-derivate und diese enthaltende coatings
DE69819963D1 (de) Schweissgegenstand und Schweissverfahren
DE69838667D1 (de) Verfahren zur stabilisierung nützlicher proteine und nützliche proteinhaltige mittel
DE69702554D1 (de) Aminopeptidase GX und damit Hydrolysierungsverfahren von Proteine
NO971505D0 (no) Trofinin og trofininhjelperproteiner
DE19881048D2 (de) Anlage und Verfahren zur Regelung des Flüssigkeitshaushaltes von Patienten
DE9411394U1 (de) Sicherungseinsatz und Sicherungshalter hierfür
ATE346840T1 (de) Aminoalkylphenol-derivate zur behandlung von depression und gedächtnis-funktionsstörung
FI965109A (fi) Hetorologisten liukenemattomien proteiinien poistaminen bakteereista

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee